Bavarian Nordic (OTCPK:BVNR.Y) - Stock Price, News & Analysis

BVNR.Y Stock Overview

Develops, manufactures, and commercializes life-saving vaccines.

BVNR.Y fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 70.7% below our estimate of its fair value

Earnings are forecast to grow 5.71% per year

Earnings grew by 227.1% over the past year

Trading at good value compared to peers and industry

Risk Analysis

Large one-off items impacting financial results

Bavarian Nordic A/S Competitors

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$1.8b

Protagonist Therapeutics

NasdaqGM:PTGX

US$1.9b

MannKind

NasdaqGM:MNKD

US$1.4b

Kiniksa Pharmaceuticals

NasdaqGS:KNSA

US$1.3b

Price History & Performance

Summary of all time highs, changes and price drops for Bavarian Nordic
Historical stock prices
Current Share Price	kr.7.44
52 Week High	kr.9.68
52 Week Low	kr.5.95
Beta	1.42
11 Month Change	-14.01%
3 Month Change	-0.17%
1 Year Change	-23.11%
33 Year Change	-44.46%
5 Year Change	-10.01%
Change since IPO	26.00%

Recent updates

Shareholder Returns

	BVNR.Y	US Biotechs	US Market
7D	-1.4%	2.1%	-0.5%
1Y	-23.1%	12.0%	24.2%

Return vs Industry: BVNR.Y underperformed the US Biotechs industry which returned 9.9% over the past year.

Return vs Market: BVNR.Y underperformed the US Market which returned 24.1% over the past year.

Price Volatility

Is BVNR.Y's price volatile compared to industry and market?
BVNR.Y volatility
BVNR.Y Average Weekly Movement	4.8%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stable Share Price: BVNR.Y has not had significant price volatility in the past 3 months.

Volatility Over Time: BVNR.Y's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1992	1,381	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.

Bavarian Nordic A/S Fundamentals Summary

How do Bavarian Nordic's earnings and revenue compare to its market cap?
BVNR.Y fundamental statistics
Market cap	US$1.76b
Earnings (TTM)	US$141.57m
Revenue (TTM)	US$955.19m

12.4x

P/E Ratio

1.8x

P/S Ratio

Is BVNR.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BVNR.Y income statement (TTM)
Revenue	kr.6.64b
Cost of Revenue	kr.2.04b
Gross Profit	kr.4.60b
Other Expenses	kr.3.62b
Earnings	kr.984.37m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 22, 2024

Earnings per share (EPS)	12.65
Gross Margin	69.29%
Net Profit Margin	14.82%
Debt/Equity Ratio	0.2%

How did BVNR.Y perform over the long term?

See historical performance and comparison

BVNR.Y Stock Overview

Rewards

Risk Analysis

Bavarian Nordic A/S Competitors

NasdaqCM:CPRX

US$1.8b

NasdaqGM:PTGX

US$1.9b

NasdaqGM:MNKD

US$1.4b

NasdaqGS:KNSA

US$1.3b

Price History & Performance

Recent News & Updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Recent updates

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial

Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries

Bavarian Nordic A/S Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma

Bavarian Nordic A/S Secures Second Part of Smallpox Vaccine Order from the U.S. Government

Health Canada Extends Approval of IMVAMUNE to Immunization Against Monkeypox and Orthopox Viruses

Bavarian Nordic A/S to Report Q2, 2021 Results on Aug 25, 2021

Bavarian Nordic A/S Announces Appointment of Anu Helena Kerns as Executive Vice President, People and Organization, Effective from November 2020

Bavarian Nordic A/S to Report Fiscal Year 2020 Results on Mar 12, 2021

Shareholder Returns

Price Volatility

About the Company

Bavarian Nordic A/S Fundamentals Summary

12.4x